Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00929474 · ClinicalTrials.gov registry record · NA
BOOST - Benefit of Frequent Optimization After Cardiac Resynchronization Therapy Device Replacement
A NA study, sponsored by Abbott Medical Devices.
- Terminated
- Registry status
- NA
- Development phase
- 17
- Enrollment target
NCT00929474: Clinical Trial NA study, sponsored by Abbott Medical Devices.
NCT00929474 is a NA study that was terminated before completion, run by Abbott Medical Devices. The registered enrollment target is 17 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00929474, a NA study, was terminated before completion, sponsored by Abbott Medical Devices.
- TERMINATED
- Registry status
- NA
- Development phase
- 17 participants
- Enrollment target
Study Summary
Cardiac resynchronization therapy (CRT) has shown improvement in mortality and morbidity in patients with left ventricular systolic dysfunction and congestive heart failure. Additionally in CRT patients it has been demonstrated that optimizing paced/sensed atrioventricular (AV) and interventricular (V-V) timings leads to immediate hemodynamic benefits and further improves cardiac function. Recent studies have shown that optimal paced/sensed AV and V-V delays change over time, which raises the question of how often optimization should be repeated. Thus, frequent re-optimization of these delays might be beneficial for maintaining significant improvement of cardiac function. However, it remains to be evaluated whether timing optimization may be beneficial on patients who have received CRT for a number of years and are now having the CRT device replaced.
Primary Outcome
The BOOST study is prematurely terminated so there were no enough numbers of patients to have a meaningful measurement.
Interventions
- DEVICE QuickOpt - SJM CRT (Group 1)
- DEVICE Control - SJM CRT (Group 2)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2009-06 |
| Est. Completion | 2010-09 |
| Phase | NA |
Why NCT00929474 stopped before completion
NCT00929474 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 17 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 2 interventions - of which QuickOpt - SJM CRT (Group 1) is the first listed.
NCT00929474 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00929474 about?
NCT00929474 is a clinical study titled "BOOST - Benefit of Frequent Optimization After Cardiac Resynchronization Therapy Device Replacement". Cardiac resynchronization therapy (CRT) has shown improvement in mortality and morbidity in patients with left ventricular systolic dysfunction and congestive heart failure. Additionally in CRT patients it has been demonstrated that optimizing paced/sensed atrioventricular (AV) and interventricular ...
What is the current status of trial NCT00929474?
This trial is currently terminated. It is a NA study. The enrollment target is 17 participants. The study started on 2009-06. Estimated completion is 2010-09.
What interventions are being tested in trial NCT00929474?
The interventions under investigation include: QuickOpt - SJM CRT (Group 1) (DEVICE), Control - SJM CRT (Group 2) (DEVICE).
Who is sponsoring clinical trial NCT00929474?
This trial is sponsored by Abbott Medical Devices, which has 261 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00929474's enrollment target sits among peer trials
17 1871st of 2000 higher than 130 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02090140 · 17 participants · NA
Microfracture Versus Adipose Derived Stem Cells for the Treatment of Articular Cartilage Defects
- NCT03317860 · 17 participants · NA
Improving Measurement and Treatment of Post-stroke Neglect
- NCT04356469 · 17 participants · Phase 2
TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Non-Malignant Hematological Disorders in Children
- NCT04414046 · 17 participants · Phase 2
TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Primary Immunodeficiency and Inherited Metabolic Disorders in Children
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia